並列摘要
Encouraging results have been reported front several large trials of tetravalent rhesus rotavirus vaccine, with efficaccy of 70-80% against severe disease. A recent Venezuelan study showed similar results to trials in USA and Europe. The vaccine may soon be licensed in USA. It provides the exciting prospect of a strategy to prevent one of the worlds major child killers. Other candidate vaccines are under development including human-bovine reassortants, neonatal strains, non-replicating rotaviruses, vector vaccines and other genetically engineered products. Second and third generation rotavirus vaccines are on the horizon. The need for a rotavirus vaccine is well accepted by paediatricians, but public health authorities need to be lobbied. Other issues which need to be addressed include relative importance of non-group A rotaviruses, possible administration with OPV, the influence of breast feeding, and most importantly, cost. It is essential that rotavirus vaccine is somehow made available to all of the worlds children, not just those in developed countries.
被引用紀錄
延伸閱讀
- 吳芷儀（2009）。淺談輪狀病毒與疫苗。彰基藥訊，17(3)，5-8。https://doi.org/10.29600/BGYY.200909.0002
- 張弘洋、李宏昌、楊俊仁、黃富源（2000）。輪狀病毒腸胃炎及其疫苗。當代醫學，(319)，373-375。https://doi.org/10.29941/MT.200005.0007
- 徐憶芬、吳奕璋、王春玉（2008）。輪狀病毒疫苗簡介。感染控制雜誌，18(1)，25-32。https://doi.org/10.6526/ICJ.200802_18(1).0003
- 黃文雄、張海山、史健生、余進光（2007）。輪狀病毒新型疫苗。臺灣兒童過敏氣喘及免疫學會學會通訊，8(1)，6-9。https://doi.org/10.7025/HEJ.200703.0006
- 陳國東、許建邦、陳豪勇、湯仁彬、黃繼慶（2000）。輪狀病毒感染。中華公共衛生雜誌，19(3)，171-179。https://doi.org/10.6288/CJPH2000-19-03-03